

**The Utah Society of Health System Pharmacists and University of Utah Hospitals and Clinics Present:  
Fall 2018 Resident Continuing Pharmacy Education Series**

**Target Audience:** Pharmacists, pharmacy technicians, and pharmacy students

<b>Date</b>	<b>Time &amp; Location</b>	<b>Presenter</b>	<b>Title, Objectives &amp; ACPE UAN</b>
10/27 Sat.	HSEB 5100B at 8:00 am	Rebecca Clark, PharmD  Mentor: Shelly Hummert, PharmD <i>Oncology Clinical Pharmacist</i>	<b>Managing Anticoagulation in Malignancy: The Choice Will Not Be in Vein</b> (0.1CEU) <b>A-0167-0000-18-026-L01-P/T</b>  <u>Pharmacist Objectives:</u> 1. Recognize risk factors for developing venous thromboembolisms (VTE) in patients with active malignancies 2. Analyze guideline recommendations for VTE prophylaxis in patients with multiple myeloma 3. Review agents used for reversal of anticoagulants 4. Choose an appropriate anticoagulation regimen for treatment of VTE in a patient with an active malignancy  <u>Technician Objectives:</u> 1. Identify anticoagulants used for prevention and treatment of cancer-associated VTE 2. Differentiate proper storage, handling, and dispensing of anticoagulants and reversal agents 3. Describe cost differences between anticoagulants
10/27 Sat.	HSEB 5100B at 9:00 am	Kelsey Turcotte, PharmD  Mentor: Courtney C. Cavaliere, PharmD, BCOP <i>Oncology Clinical Pharmacist</i>	<b>Prevention Intervention Comprehension: Understanding Cancer Preventative Pharmacologic Agents</b> (0.1CEU) <b>A-0167-0000-027-L01-P/T</b>  <u>Pharmacist Objectives:</u> 1. Identify medications and supplements that may be utilized as cancer-preventative pharmacologic agents (CPPAs) 2. Review lung, breast, colon, and prostate cancer risk factors and screening suggestions based on current guidelines 3. Distinguish between evidence based and non-evidence based CPPAs 4. Formulate a recommendation for CPPAs based on a patient's characteristics  <u>Technician Objectives:</u> 1. Recall medications that have evidence of cancer-preventative pharmacologic agents (CPPAs) 2. Distinguish CPPAs that can be obtained over the counter versus through a prescription 3. Identify patients that may be candidates for pharmacist counseling regarding the use of CPPAs 4. Recognize resources used to determine risk factors and screening suggestions for lung, breast, colon, and prostate cancers
10/27 Sat.	HSEB 5100B at 10:00 am	Rebecca Martin, PharmD  Mentors: Anna Beck, MD <i>Breast Cancer and Supportive Oncology and Survivorship Physician</i>  Steve Kirkegaard, PharmD <i>Oncology Clinical Pharmacist</i>	<b>Life After Cancer: The Battle is Won, But the War is Not Over</b> (0.1CEU) <b>A-0167-0000-18-028-L01-P/T</b>  <u>Pharmacist Objectives:</u> 1. Describe common complications of life after cancer 2. Analyze limitations of current literature and data of supportive care plans 3. Discuss gaps of current supportive care plan structures 4. Identify resources for management of cancer survivorship complications  <u>Technician Objectives:</u> 1. Describe common complications of life after cancer 2. Recall medications that have evidence for psychologic treatment in cancer survivors 3. Recall medications that have evidence for sexual dysfunction in cancer survivors

10/27 Sat.	HSEB 5100B at 11:30 am	Rachael Freeman, PharmD  Mentor: Christine Jamjian, PharmD, AAHIVP <i>HIV Clinical Pharmacist</i>	<p style="text-align: center;"><b>Anything but Retro: Updates to HIV Therapy Options</b> (0.1CEU) <b>A-0167-0000-18-029-L02-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Review the relevant history of HIV infections and therapy in the US</li> <li>2. Appraise newly approved agents for treatment of HIV</li> <li>3. Examine the role of the new dolutegravir warning in treatment of HIV in pregnancy</li> <li>4. Recognize drugs in the research pipeline for treatment of HIV</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize the names of newly approved HIV therapy and their dosage regimens</li> <li>2. Demonstrate where to find information on preparation of ibalizumab</li> <li>3. Recognize drugs in the research pipeline for treatment of HIV</li> </ol>
10/27 Sat.	HSEB 5100B at 12:30 pm	Brandon Tritle, PharmD  Mentor: Tristan Timbrook, PharmD, MBA, BCPS <i>Infectious Diseases Clinical Pharmacist</i>	<p style="text-align: center;"><b>Fortnights and Football Scores: Evaluating Evidence Based Durations of Antibiotic Therapy</b> (0.1CEU) <b>A-0167-0000-18-030-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize the benefits of appropriate durations of antimicrobial therapy</li> <li>2. Identify infectious disease states with studies into appropriate duration of antimicrobial therapy</li> <li>3. Compare guideline recommended durations of therapy with primary literature</li> <li>4. Distinguish patients appropriate for shorter durations of therapy</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize the benefits of appropriate durations of antimicrobial therapy</li> <li>2. Criticize myths around antibiotic treatment courses</li> <li>3. Differentiate patients who may have longer courses of antibiotics dispensed</li> </ol>
10/30 Tue.	HSEB 5100C at 3:00 pm	Azelia Brown, PharmD  Mentors: Tom Peterson, PharmD, BCPS <i>Neonatal ICU Clinical Pharmacist</i>  Cole Sloan, PharmD, BCPS <i>Emergency Medicine Clinical Pharmacist</i>	<p style="text-align: center;"><b>Baby On Board! Management of the Critically Ill Obstetric Patient</b> (0.1CEU) <b>A-0167-0000-18-031-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Evaluate the different stages of pregnancy and contraindicated medications</li> <li>2. Compare and contrast the clinical presentations of common obstetric emergencies</li> <li>3. Prepare appropriate medication regimens for the management of ante- and post-partum complications</li> <li>4. Choose an appropriate sedation and vasopressor regimen for obstetric patients requiring these interventions</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize the potential consequences of inappropriate medication use during pregnancy</li> <li>2. Review common pregnancy complications that may require pharmacological intervention</li> <li>3. Identify medications that are contraindicated in pregnant patients and medications associated with the treatment of obstetric emergencies</li> <li>4. Distinguish between high priority medications and normal medication regimens used in the management of obstetric patients</li> </ol>

10/30 Tue.	HSEB 5100C at 4:00 pm	Jo Zhou, PharmD  Mentor: Erin Lingenfelter, PharmD <i>Emergency Medicine Clinical Pharmacist</i>	<p align="center"><b>New Drugs on the Block: Novel Therapies in Critical Care Medicine</b> (0.1CEU) <b>A-0167-0000-18-032-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>List FDA-approved indications for angiotensin II, andexanet alpha, clevidipine, and sugammadex</li> <li>Describe the mechanism of action for the medications</li> <li>Analyze the current literature regarding the safety and efficacy of these medications</li> <li>Apply knowledge of these medications into clinical scenarios for FDA-approved indications</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>Name the generic and brand name for the following products: angiotensin II, andexanet alpha, clevidipine, and sugammadex</li> <li>Identify cost differences of these medications</li> <li>Manage proper storage, handling, and preparation of angiotensin II, andexanet alpha, clevidipine, and sugammadex</li> </ol>
11/1 Thu.	HSEB 2680 at 3:00 pm	Lynsi Collins, PharmD  Mentor: Ryan McTish, PharmD <i>Neurosciences Clinical Pharmacist</i>	<p align="center"><b>Can't Stop, Won't Stop: Drug-Induced Movement Disorders</b> (0.1CEU) <b>A-0167-0000-18-033-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>Investigate the pathophysiology, risk factors, and medical management of drug-induced movement disorders</li> <li>Evaluate current treatment strategies and guideline recommendations for the management of drug-induced movement disorders</li> <li>Identify the clinical challenge of deciding how to manage drug-induced movement disorders</li> <li>Construct evidence-based recommendations for the management of drug-induced movement disorders</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>Identify specific drugs and medication classes commonly associated with causing drug-induced movement disorders</li> <li>Analyze symptoms and complications of drug-induced movement disorders</li> <li>Recognize treatment strategies used in the management of drug-induced movement disorders</li> </ol>
11/1 Thu.	HSEB 2680 at 4:00 pm	Rebecca Miller, PharmD  Mentor: Jennifer Babin, PharmD <i>Internal Medicine Clinical Pharmacist and Assistant Professor</i>	<p align="center"><b>The Clot Thickens: Thromboembolic Complications of Cirrhosis</b> (0.1CEU) <b>A-0167-0000-18-034-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>Analyze the pathophysiological changes in cirrhosis leading to both bleeding and thrombotic complications</li> <li>Recognize risk factors for bleeding and thrombosis in patients with cirrhosis</li> <li>Recall the impact of cirrhosis on laboratory values used to evaluate anticoagulation</li> <li>Evaluate the different anticoagulation options for prophylaxis and treatment of venous thromboemboli (VTE) in cirrhosis</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>Recognize why patients with cirrhosis are at risk for both bleeding and thrombotic events</li> <li>Identify laboratory values used to monitor anticoagulation that are altered in cirrhosis</li> <li>Differentiate between treatment options for VTE in cirrhosis</li> </ol>
11/3 Sat.	HSEB 5100B at 8:00 am	Mika Jankowski, PharmD  Mentor: Alyson Clough, PharmD, BCOP <i>BMT/Hematology Clinical Pharmacist</i>	<p align="center"><b>Hits and Blunted Effects: Clinical Implications of Marijuana in Patients with Cancer</b> (0.1CEU) <b>A-0167-0000-18-035-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>Review pathways and mechanisms of the endogenous cannabinoid system in the body</li> <li>Examine the pharmacology, pharmacokinetics and pharmacodynamics of cannabinoid products.</li> <li>Evaluate the potential risks of cannabinoid products in cancer patients</li> </ol> <p align="right"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>Distinguish FDA approved cannabinoid agents from unregulated agents or agents in development.</li> <li>Recognize different cannabinoid formulations available.</li> <li>Identify common adverse effects of cannabinoid products.</li> </ol>

11/3 Sat.	HSEB 5100B at 9:00 am	Keaton Crockett, PharmD  Mentor: Alisyn May PharmD, BCACP, CDE <i>Family Medicine Clinical Pharmacist and Assistant Professor</i>	<p style="text-align: center;"><b>Adult ADHD and Stimulant Use: the Emerging, Overshadowed Epidemic</b> (0.1CEU) <b>A-0167-0000-18-036-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Discuss appropriate stimulant use in adults diagnosed with ADHD</li> <li>2. Examine diagnostic criteria for adult ADHD</li> <li>3. Identify stimulant adverse effects and the impact of stimulant use on comorbid conditions</li> <li>4. Investigate elements of appropriate stimulant prescribing and use</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Identify common stimulants used to treat ADHD</li> <li>2. Discuss appropriate stimulant use in adults diagnosed with ADHD</li> <li>3. Differentiate elements of legitimate vs. illegitimate stimulant prescriptions</li> </ol>
11/3 Sat.	HSEB 5100B at 10:00 am	Sabrina Sherwood, PharmD  Mentor: Kami Roake, PharmD <i>Gastroenterology Clinical Pharmacist</i>	<p style="text-align: center;"><b>Inflammatory Bowel Disease</b> (0.1CEU) <b>A-0167-0000-18-037-L01-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Analyze expert guidelines for Crohn's Disease and Ulcerative Colitis management</li> <li>2. Recall the pharmacology of agents used in IBD therapy management</li> <li>3. Evaluate supportive evidence for IBD therapy management recommendations</li> <li>4. Construct a therapeutic regimen and monitoring plan for a patient with IBD</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Outline the signs and symptoms of IBD</li> <li>2. Identify both the brand, generic, and biosimilar names for commonly used IBD medications</li> <li>3. Demonstrate how to assist patients in gaining accessibility to and financial assistance for IBD medications</li> </ol>
11/3 Sat.	HSEB 5100B at 11:30 am	Louie Dunn, PharmD  Mentor: Dawnyle Kelley, PharmD <i>Informatics Pharmacist</i>	<p style="text-align: center;"><b>There's a Wearable for That: New Technologies and Principles of Data Gathering and Analysis</b> (0.1CEU) <b>A-0167-0000-18-038-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. List common types of wearables and their uses in healthcare and personal wellness</li> <li>2. Evaluate abilities and limitations of a wearable prior to selecting it for use in a clinical trial</li> <li>3. Interpret data generated by patient wearables</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. List common types of wearables and their uses in healthcare and personal wellness</li> <li>2. Recognize trends in health and wellness-associated wearables use</li> <li>3. Question data generated by patient wearables</li> </ol>

11/3 Sat.	HSEB 5100B at 12:30 pm	Alex Lux, PharmD  Mentor: Ashley Kappenman, PharmD, MS, BCPS <i>Ambulatory Clinical Care Center Pharmacy Supervisor</i>	<p style="text-align: center;"><b>Fake it Till You Make it: Dissecting the Imposter Syndrome</b> (0.1CEU) <b>A-0167-0000-18-039-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Explain the imposter syndrome</li> <li>2. Assess symptoms of imposter syndrome in learners</li> <li>3. Compare and contrast ways to coach learners with imposter syndrome</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Recognize how imposter syndrome presents differently in different groups</li> <li>2. Recognize symptoms of imposter syndrome</li> <li>3. Apply methods of coping with imposter syndrome</li> </ol>
11/3 Sat.	HSEB 5100B at 1:30 pm	Shea O'Brien, PharmD, MBA  Mentor: Karen Thomas, PharmD, PhD <i>Ambulatory Clinical Care Center Pharmacy Supervisor</i>	<p style="text-align: center;"><b>What's so Special About Specialty Pharmacy?</b> (0.1CEU) <b>A-0167-0000-18-040-L04-P/T</b></p> <p><u>Pharmacist Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Compare and contrast specialty and traditional retail pharmacies</li> <li>2. Categorize specialty and non-specialty medications</li> <li>3. Discuss controversies surrounding cost and access to specialty drugs</li> <li>4. Describe pharmacists' role in specialty pharmacy</li> </ol> <p style="text-align: right;"><u>Technician Objectives:</u></p> <ol style="list-style-type: none"> <li>1. Compare and contrast specialty and traditional retail pharmacies</li> <li>2. Categorize specialty and non-specialty medications</li> <li>3. Discuss controversies surrounding cost and access to specialty drugs</li> <li>4. Describe technicians' role in specialty pharmacy</li> </ol>

\*A=application-based CE

**Registration, Info & Fees:** All presentations are one hour. The cost is \$55 for pharmacists, \$25 for pharmacy residents, and \$15 for technicians to attend regardless of the number of hours or sessions attended. You may also pay \$10 for every individual CE you attend. This fee can be paid online at [www.ushp.org](http://www.ushp.org). No RSVP is required for the weekday sessions, but registration for the Saturday events on 10/27/18 and 11/3/18 are required to ensure a sufficient number of handouts are printed. Seating is limited. To receive CE (Continuing Education) credit, you must be a USHP member. If you are interested in joining USHP, please visit our website [www.ushp.org](http://www.ushp.org) and join online.

**Webex Meeting Information**

*Join from a video system or application*

**Credit Hours:** Through attending this program, up to 15.0 contact hours (0.15 CEUs) can be attained. If attending in person or using the WebEx option for CE credit, a participation code will be provided during each presentation. Participants must be a member of USHP, register and pay for the series or individual sessions, and complete evaluation surveys for each day attended. The links to these surveys are available on the USHP website and must be completed within 7 days of each day of CE attendance. A participation code will be required to get credit for each day. You must register and pay for the CE Series by 11/4/18.

**Special Accommodations:** If you are in need of any special accommodation, please contact us a minimum of 2 days prior to the program in order to make arrangements at the below listed contact.

**Commercial Support:** No commercial support was received for this program.

**Questions?** Contact Sara deHoll ([sara.deholl@utah.edu](mailto:sara.deholl@utah.edu)), Stacy Prelewicz ([stacy.prelewicz@hci.utah.edu](mailto:stacy.prelewicz@hci.utah.edu)), or Emma Jones ([emma.jones@hci.utah.edu](mailto:emma.jones@hci.utah.edu))



The Utah Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.